Oragenics - die grüne Pille für das Depot... (Seite 348)
eröffnet am 12.01.21 11:07:28 von
neuester Beitrag 20.04.24 12:26:31 von
neuester Beitrag 20.04.24 12:26:31 von
Beiträge: 8.302
ID: 1.338.290
ID: 1.338.290
Aufrufe heute: 5
Gesamt: 740.147
Gesamt: 740.147
Aktive User: 0
ISIN: US6840235005 · WKN: A3D386 · Symbol: OGEN
6,9000
EUR
0,00 %
0,0000 EUR
Letzter Kurs 23.01.23 Berlin
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 38,27 | +28,16 | |
| 8,0780 | +27,90 | |
| 10,155 | +21,04 | |
| 8,1400 | +20,41 | |
| 3,6100 | +17,51 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6700 | -26,58 | |
| 2,1300 | -34,41 | |
| 3,1600 | -38,64 | |
| 1,7000 | -49,40 | |
| 125,00 | -95,83 |
Beitrag zu dieser Diskussion schreiben
Feedback!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: Spam, Werbung!
Dieser Beitrag wurde von CloudMOD moderiert. Grund: Spam, Werbung
In der Tat! Aktien haben nun mal die dumme Angewohnheit, daß sie auch fallen können und nicht das machen was man gerne (evtl auch noch schnell) hätte...
Die viel Interessantere Frage, abseits von Oragenics ist, wie die Gesamtmarktlage derzeit eigentlich so ausschaut. Es könnte nämlich durchaus sein, daß die Märkte jetzt an einem Punkt angelangt sind, an dem es nicht mehr weiter nach oben geht. Eine Korrektur wäre überfällig. Einzelne Aktien, vor allem FANGs tragen den Markt derzeit alleine, wärend andere bereits massivst im korigieren sind. Wie schätzen dies die anderen ein? Wird die liquiditätsgetriebene-inflationäre Hausse weitergehen, oder kommt die Korrektur weil die Wachstumsraten in diesem Tempo nicht durchzuhalten sind?
Die viel Interessantere Frage, abseits von Oragenics ist, wie die Gesamtmarktlage derzeit eigentlich so ausschaut. Es könnte nämlich durchaus sein, daß die Märkte jetzt an einem Punkt angelangt sind, an dem es nicht mehr weiter nach oben geht. Eine Korrektur wäre überfällig. Einzelne Aktien, vor allem FANGs tragen den Markt derzeit alleine, wärend andere bereits massivst im korigieren sind. Wie schätzen dies die anderen ein? Wird die liquiditätsgetriebene-inflationäre Hausse weitergehen, oder kommt die Korrektur weil die Wachstumsraten in diesem Tempo nicht durchzuhalten sind?
Ihr
vergiftet mit Euren zwichtigkeiten das Forum
Antwort auf Beitrag Nr.: 68.804.240 von Nordsturm am 17.07.21 10:25:21Sie vergleichen sich mit Warren Buffet?
Ich lach mich schief.
Ich lach mich schief.
Trading Spotlight
Vielleicht bekommt ja Oragenics auch mal was ab
https://www.commerce.gov/news/press-releases/2021/07/secreta…
Secretary Raimondo Announces $153 Million to Promote Innovation in Biopharmaceutical Manufacturing
$83 million in funding comes from the American Rescue Plan to support research and development to prevent, prepare for and respond to coronavirus outbreaks
Manufacturing
Gina M. Raimondo
FOR IMMEDIATE RELEASE
Wednesday, July 14, 2021
Office of Public Affairs
publicaffairs@doc.gov
The U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) has made two awards totaling $153 million to the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The awards were announced today by U.S. Secretary of Commerce Gina Raimondo at the NIIMBL annual meeting in Washington, D.C.
NIIMBL is a public-private partnership designed to accelerate innovation in the U.S. biopharmaceutical industry, which produces vaccines, monoclonal antibodies, gene therapies and other medical products derived from biological sources. NIIMBL is a Manufacturing USA® institute sponsored by the Department of Commerce.
“I am so pleased that NIIMBL will continue to bring together organizations of all types to help strengthen our nation through better pandemic preparedness and a more agile manufacturing industry,” said Secretary Raimondo, who was joined at the NIIMBL meeting by Senator Chris Coons of Delaware, Acting Commissioner of the Food and Drug Administration Janet Woodcock and Director of the FDA’s Center for Biologics Evaluation and Research Peter Marks. “This important investment for America, funded in part by President Biden’s American Rescue Plan, will help meet the nation’s need for lifesaving biopharmaceuticals.”
The first award renews NIST’s federal sponsorship of NIIMBL, providing $70 million over five years with an equal, non-federal cost-matching requirement. This award will allow NIIMBL to continue driving innovation in domestic biopharmaceutical manufacturing by developing flexible, agile and cost-effective manufacturing processes that can be scaled up quickly and are less reliant on foreign supply chains.
NIST will also provide $83 million to NIIMBL over three years from the American Rescue Plan to support research and development to prevent, prepare for and respond to coronavirus outbreaks.
During the COVID-19 pandemic, scientific and manufacturing innovation delivered vaccines in record time. The new funding will enable NIIMBL efforts to help transform this emergency response into a sustainable, ongoing effort to address the continuing coronavirus threat. NIIMBL will do this by developing efficient, robust processes for manufacturing vaccines and therapeutics for COVID-19 and other coronavirus strains that could emerge in the future.
As part of this effort, NIIMBL will work to increase the shelf life and reduce the amount of refrigeration required for messenger RNA vaccines, boost capabilities for rapid production of antigens used in testing and screening for new variants and develop novel technologies for detecting counterfeit vaccines, among other things.
NIIMBL works on challenges that are too big for any single organization to address. The institute brings together more than 180 members, including biopharmaceutical and biotechnology companies, raw materials suppliers, equipment and product manufacturers, academic research institutions, state governments and nonprofit organizations focused on global health initiatives and workforce development. Every $1 of federal investment in NIIMBL has been matched by $1.80 in funding from NIIMBL member organizations.
Since NIIMBL was launched in 2017, its efforts have led to better diagnostic testing and plasma donor screening, an injectable antibody therapeutic that reduces the need for intravenous administration, and improved supply chain models for meeting surging demand during COVID outbreaks.
To learn more about NIIMBL, visit the institute’s website.
The Manufacturing USA institutes and their sponsors, the U.S. Departments of Commerce, Defense and Energy, connect more than 2,000 organizations across hundreds of major projects to quickly move technology from laboratory prototypes to industrial capabilities and provide thousands of people with advanced manufacturing knowledge and skills. To learn more about Manufacturing USA, visit www.ManufacturingUSA.com.
NIST promotes U.S. innovation and industrial competitiveness by advancing measurement science, standards and technology in ways that enhance economic security and improve our quality of life. To learn more about NIST, visit
https://www.commerce.gov/news/press-releases/2021/07/secreta…
Secretary Raimondo Announces $153 Million to Promote Innovation in Biopharmaceutical Manufacturing
$83 million in funding comes from the American Rescue Plan to support research and development to prevent, prepare for and respond to coronavirus outbreaks
Manufacturing
Gina M. Raimondo
FOR IMMEDIATE RELEASE
Wednesday, July 14, 2021
Office of Public Affairs
publicaffairs@doc.gov
The U.S. Department of Commerce’s National Institute of Standards and Technology (NIST) has made two awards totaling $153 million to the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The awards were announced today by U.S. Secretary of Commerce Gina Raimondo at the NIIMBL annual meeting in Washington, D.C.
NIIMBL is a public-private partnership designed to accelerate innovation in the U.S. biopharmaceutical industry, which produces vaccines, monoclonal antibodies, gene therapies and other medical products derived from biological sources. NIIMBL is a Manufacturing USA® institute sponsored by the Department of Commerce.
“I am so pleased that NIIMBL will continue to bring together organizations of all types to help strengthen our nation through better pandemic preparedness and a more agile manufacturing industry,” said Secretary Raimondo, who was joined at the NIIMBL meeting by Senator Chris Coons of Delaware, Acting Commissioner of the Food and Drug Administration Janet Woodcock and Director of the FDA’s Center for Biologics Evaluation and Research Peter Marks. “This important investment for America, funded in part by President Biden’s American Rescue Plan, will help meet the nation’s need for lifesaving biopharmaceuticals.”
The first award renews NIST’s federal sponsorship of NIIMBL, providing $70 million over five years with an equal, non-federal cost-matching requirement. This award will allow NIIMBL to continue driving innovation in domestic biopharmaceutical manufacturing by developing flexible, agile and cost-effective manufacturing processes that can be scaled up quickly and are less reliant on foreign supply chains.
NIST will also provide $83 million to NIIMBL over three years from the American Rescue Plan to support research and development to prevent, prepare for and respond to coronavirus outbreaks.
During the COVID-19 pandemic, scientific and manufacturing innovation delivered vaccines in record time. The new funding will enable NIIMBL efforts to help transform this emergency response into a sustainable, ongoing effort to address the continuing coronavirus threat. NIIMBL will do this by developing efficient, robust processes for manufacturing vaccines and therapeutics for COVID-19 and other coronavirus strains that could emerge in the future.
As part of this effort, NIIMBL will work to increase the shelf life and reduce the amount of refrigeration required for messenger RNA vaccines, boost capabilities for rapid production of antigens used in testing and screening for new variants and develop novel technologies for detecting counterfeit vaccines, among other things.
NIIMBL works on challenges that are too big for any single organization to address. The institute brings together more than 180 members, including biopharmaceutical and biotechnology companies, raw materials suppliers, equipment and product manufacturers, academic research institutions, state governments and nonprofit organizations focused on global health initiatives and workforce development. Every $1 of federal investment in NIIMBL has been matched by $1.80 in funding from NIIMBL member organizations.
Since NIIMBL was launched in 2017, its efforts have led to better diagnostic testing and plasma donor screening, an injectable antibody therapeutic that reduces the need for intravenous administration, and improved supply chain models for meeting surging demand during COVID outbreaks.
To learn more about NIIMBL, visit the institute’s website.
The Manufacturing USA institutes and their sponsors, the U.S. Departments of Commerce, Defense and Energy, connect more than 2,000 organizations across hundreds of major projects to quickly move technology from laboratory prototypes to industrial capabilities and provide thousands of people with advanced manufacturing knowledge and skills. To learn more about Manufacturing USA, visit www.ManufacturingUSA.com.
NIST promotes U.S. innovation and industrial competitiveness by advancing measurement science, standards and technology in ways that enhance economic security and improve our quality of life. To learn more about NIST, visit
Antwort auf Beitrag Nr.: 68.803.931 von Indextrader24 am 17.07.21 09:21:48
Vielleicht verstehen sie irgendwann einmal, warum Warren Buffett Erfolge hat, obwohl er kein Experte für die Branche ist, in die er investiert. Ich hoffe es für Sie.
Zitat von Indextrader24: Das sagt jemand der von Medizin keinen blassen Schimmer hat. Was für eine Selbstgefälligkeit und Anmaßung. 🤦🤦🤦
Vielleicht verstehen sie irgendwann einmal, warum Warren Buffett Erfolge hat, obwohl er kein Experte für die Branche ist, in die er investiert. Ich hoffe es für Sie.
Antwort auf Beitrag Nr.: 68.802.806 von fypet am 16.07.21 22:32:07Da ist jemand der selektiven Wahrnehmung anheim gefallen. Wir befinden uns mehr als 1000 Dollar vom Allzeithoch entfernt.
Die Argumentation ist echt köstlich.
Die Argumentation ist echt köstlich.
Antwort auf Beitrag Nr.: 68.798.006 von Wolfirainbow am 16.07.21 14:37:53Es wurde erst persönlich und dann ging der Kurs nach unten. Die Art und Weise wie die Permabashet dabei vorgehen ist mit dem Wort kriminell nur unzureichend beschrieben.
Da werden falsche Tatsachenbehauptungen verbreitet und in 24/7 Manier üble Nachrede - auch dem Unternehmen gegenüber betrieben.
Man Frage sich warum solche "Lichtgestalten" hier Tage in tagaus detartig agieren. Gestalten, die nicht einmal wissen, was ein Peptid ist.
Das sie das Schreiben, was sie schreiben überrascht mich eigentlich nicht. Passt aber zum Kindergartenniveau in welches dieses Forum abgerutscht ist.
Hier zu schreiben ist inzwischen reinste Zeitverschwendung angesichts des erreichten Diskussionsniveaus.
Erfreulicherweise hat aber Oragenics nun erstmalig meine Fragenkatalog beantwortet.
Zumindest die Unternehmenskommunikation ist sich am verbessern.
Da werden falsche Tatsachenbehauptungen verbreitet und in 24/7 Manier üble Nachrede - auch dem Unternehmen gegenüber betrieben.
Man Frage sich warum solche "Lichtgestalten" hier Tage in tagaus detartig agieren. Gestalten, die nicht einmal wissen, was ein Peptid ist.
Das sie das Schreiben, was sie schreiben überrascht mich eigentlich nicht. Passt aber zum Kindergartenniveau in welches dieses Forum abgerutscht ist.
Hier zu schreiben ist inzwischen reinste Zeitverschwendung angesichts des erreichten Diskussionsniveaus.
Erfreulicherweise hat aber Oragenics nun erstmalig meine Fragenkatalog beantwortet.
Zumindest die Unternehmenskommunikation ist sich am verbessern.
Antwort auf Beitrag Nr.: 68.801.576 von Nordsturm am 16.07.21 19:55:26Das sagt jemand der von Medizin keinen blassen Schimmer hat. Was für eine Selbstgefälligkeit und Anmaßung. 🤦🤦🤦
Durchsuchen
Oragenics - die grüne Pille für das Depot...
